NCT07623174Recruiting
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
FRAMEWORK-CRC: Fruquintinib Real-World Outcomes in mCRC - A Prospective Study of One-Year Progression-Free Survival and Overall Survival in Polish Patients
Source: ClinicalTrials.gov · Last updated 22 Sept 2026
Brief summary (registry, in English)
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body. This cancer can be hard to treat because it can behave differently from one person to another. Over time, treatments may stop working, and side effects can build up. In later treatment stages, there are only a few standard medicine options available. Because of this, studies often look at both how long people live and how treatment affects quality of life. The main aim of this study is to see how long adults in Poland with mCRC live without their cancer getting worse (progression-free survival or PFS) when they receive fruquintinib after at least two previous treatments. Fruquintinib (TAK 113) is a medicine taken by mouth that is designed to slow tumor growth. Other aim is to find out how long adults in Poland with mCRC live while being treated with fruquintinib (overall survival or OS). The study also wants to record how fruquintinib is used in routine care in adults with mCRC in Poland (for example when treatment starts, changes in doses, and how long treatment continues). Another aim is to learn about people with mCRC, such as their medical history and past treatment as well as their quality of life while they are in the study. The study will look at data already existing in the participants' medical charts.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 110 (estimated)
- First submitted
- 29 May 2026
- Start date
- 13 Aug 2026
- Primary completion date
- 31 Mar 2028
- Lead sponsor
- Takeda
- Diseases
- Colorectal cancer
- NCT number
- NCT07623174
What you commit to
- Study type: Observational
- Planned participants: 110
- From 13 Aug 2026 to the primary completion date, 31 Mar 2028
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Participant currently participates or plans to participate in an interventional clinical trial.
Who the study is looking for
- Adult participants (aged 18 years and older) with mCRC who are eligible for treatment with fruquintinib under the national drug program B.4 and will receive fruquintinib as third or subsequent line treatment after progression on or intolerance to trifluride/tipiracil.
- Participants who signed informed consent to participate in the study at the time of enrollment and prior to the fruquintinib treatment initiation.
- Participants for whom adequate medical records are available to support the data collection requirements.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bialostockie Centrum Onkologii im. M. Sklodowskiej-Curie w Bialymstoku, Oddzial Onkologii Klinicznej im. dr E. Pileckiej z pododdzialem Chemioterapii Dziennej Coordinator of this site? Confirm its status | Bialystok | Poland | Recruiting |
| Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy, Ambulatorium Chemoterapii Coordinator of this site? Confirm its status | Bydgoszcz | Poland | Not yet recruiting |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej Coordinator of this site? Confirm its status | Gliwice | Poland | Not yet recruiting |
| Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Onkologii Coordinator of this site? Confirm its status | Krakow | Poland | Not yet recruiting |
| Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie, Klinika Chorob Metabolicznych i Immunoonkologii, Oddzial Onkologii Klinicznej Coordinator of this site? Confirm its status | Lublin | Poland | Recruiting |
| Samodzielny Publiczny Zaklad Opieki Zdrowotnej Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarowskiego w Opolu, Klinika Onkologii, Odcinek Dzienny Coordinator of this site? Confirm its status | Opole | Poland | Not yet recruiting |
| Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej Curie, Oddzial Onkologii Klinicznej i Immunoonkologii z Pododdzialem Dziennym i Izb Przyjec Coordinator of this site? Confirm its status | Poznan | Poland | Not yet recruiting |
| Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu, Oddzial Onkologiczny z Pod. Dziennej Chemioterapii Coordinator of this site? Confirm its status | Przemyśl | Poland | Recruiting |
| Zachodniopomorskie Centrum Onkologii, Oddzial Onkologii Klinicznej Coordinator of this site? Confirm its status | Szczecin | Poland | Not yet recruiting |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Onkologii i Radioterapii Coordinator of this site? Confirm its status | Warsaw | Poland | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.